X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

By Brian Newell  |    July 29, 2022
During a widely attended media briefing, physicians, biopharmaceutical leaders, and a brave cancer survivor, all expressed their strong opposition to the extreme drug pricing bill Congress is...   Read More

The Senate’s latest price setting proposal will undermine: Our health care system

By Nicole Longo  |    July 28, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Senate’s latest price setting proposal will undermine: American medical innovation

By Nicole Longo  |    July 27, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Senate’s latest price setting proposal will undermine: Patient access to medicines

By Nicole Longo  |    July 26, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

Patent policy changes proposed by USPTO and FDA would leave patients behind

By Megan Van Etten  |    July 22, 2022
Kathi Vidal, Director of the USPTO, and Robert M. Califf, FDA Commissioner, recently outlined several policy areas where they plan to collaborate on addressing drug pricing. PhRMA supports the goal...   Read More

The Patient Perspective: Government price-setting harms patients

By Andrew Powaleny  |    July 22, 2022
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed...   Read More

Survey Says: Prescription drug prices are not fueling inflation concerns for Americans

By Cynthia Hicks  |    July 22, 2022
Overall inflation has surged by 9.1% since June of last year. Meanwhile, according to the Bureau of Labor Statistics, prices for prescription medicines grew by just 2.5%. As policymakers look to...   Read More

New research shows competition driven by biosimilars helps control costs in Part B

By Gabby Migliara  |    July 19, 2022
Discussions about spending in Medicare Part B, including a recent report from the Medicare Payment Advisory Commission, or MedPAC, too often overlook how competition between medicines drives down the...   Read More

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

By Tim McClung  |    July 18, 2022
PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for a...   Read More

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

By Megan Van Etten  |    July 15, 2022
Member states of the World Trade Organization (WTO) recently agreed to a waiver of intellectual property (IP) protections for COVID-19 vaccines as part of the Trade-Related Aspects of Intellectual...   Read More

Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US

By Scott LaGanga  |    July 14, 2022
Our industry continues working to improve patient access and affordability for medicines at the state level. I recently had the opportunity to connect with PhRMA board member Mark Reisenauer,...   Read More

ICYMI: Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

By Andrew Powaleny  |    July 14, 2022
A new report released by the U.S. Centers for Disease Control and Prevention (CDC) shows the number of antimicrobial-resistant (AMR) infections rose dramatically during the first year of the COVID-19...   Read More

Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

By Tom Wilbur  |    July 12, 2022
As policymakers race to pass government price setting policies, it’s important to examine true public sentiment around such proposals. Voters have made clear that they do not support policies such as...   Read More

Word of the Month: Biomarkers and surrogate endpoints

By Matthew Norawong  |    July 11, 2022
What is a biomarker?   Read More

Patients win as West Virginia implements first-in-nation share the savings policy

By Reid Porter  |    July 8, 2022
West Virginia took a big step towards making insurance work like it should last week. As of July 1, thanks to bipartisan state legislation passed and signed by the Governor in 2021, insurers and...   Read More

By the Numbers: Patients lose when the government sets prices

By Nicole Longo  |    July 8, 2022
Yet again, Congress is considering harmful drug pricing policies with complete disregard for the negative impact they will have on patients and our economy. At the same time, they are continuing to...   Read More

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

By John Corea  |    July 7, 2022
As the world braves year three of the COVID-19 pandemic and confronts a virus that continues to evolve and challenge us, we’ve come a long way in how we combat this ongoing threat. Since the start of...   Read More

3 things voters are concerned about when it comes to their health care coverage

By Cynthia Hicks  |    July 7, 2022
A recent Ipsos/PhRMA survey of more than 2,500 registered voters paints a clear picture of health care issues that keep them up at night: insurance coverage and out-of-pocket costs. Voters voice...   Read More

Prescription drug prices are not fueling inflation

By Sarah Sutton  |    July 6, 2022
Inflation is causing pain for people across the country. As policymakers search for ways to help provide relief, some are erroneously tying inflation to prescription medicines. To make matters worse,...   Read More

Counterfeit pills on social media are a stark reminder of how importation schemes could further threaten patient lives

By Gabby Migliara  |    July 6, 2022
Last month, as part of efforts to advance legislation reauthorizing the critical U.S. Food and Drug Administration (FDA) user fee agreements, the Senate HELP Committee included a dangerous proposal...   Read More

ICYMI: Antimicrobial resistance spotlighted as growing public health threat

By Andrew Powaleny  |    July 6, 2022
On June 28, PhRMA Chief Operating Officer Lori Reilly joined Executive Director of CARB-X, Kevin Outterson, Esq., and Interim Secretariat Lead of the Global Antimicrobial Resistance (AMR) R&D Hub,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."